Asset
BIDRIDISTROGENE XEBOPARVOVEC
Sarepta Therapeutics Inc. Common Stock (DE)
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05876780 | phase1 | active_not_recruiting | 2022-12-19 | 2028-08-28 | Sarepta Therapeutics, Inc. | A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency) |
| NCT06246513 | phase3 | active_not_recruiting | 2024-01-15 | 2025-03-04 | Sarepta Therapeutics, Inc. | A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 |
| NCT03652259 | phase1_2 | terminated | 2018-10-27 | 2025-01-14 | Sarepta Therapeutics, Inc. | Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency) |
FDA applications (0)
This company has no applications containing this asset.